A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts
Background: Although the durable efficacy of immune checkpoint inhibitors (ICIs) in BLCA has been confirmed in numerous studies, not all patients benefit from their application in the clinic. Platelets are increasingly being found to be closely associated with cancer progression and metastasis; howe...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1187700/full |
| _version_ | 1797833575275429888 |
|---|---|
| author | Dingshan Deng Dingshan Deng Xiaowen Li Tiezheng Qi Yuanqing Dai Yuanqing Dai Neng Liu Neng Liu Huihuang Li Huihuang Li |
| author_facet | Dingshan Deng Dingshan Deng Xiaowen Li Tiezheng Qi Yuanqing Dai Yuanqing Dai Neng Liu Neng Liu Huihuang Li Huihuang Li |
| author_sort | Dingshan Deng |
| collection | DOAJ |
| description | Background: Although the durable efficacy of immune checkpoint inhibitors (ICIs) in BLCA has been confirmed in numerous studies, not all patients benefit from their application in the clinic. Platelets are increasingly being found to be closely associated with cancer progression and metastasis; however, their comprehensive role in BLCA remains unclear.Methods: We comprehensively explored platelet expression patterns in BLCA patients using an integrated set of 244 related genes. Correlations between these platelet patterns with tumor microenvironment (TME) subtypes, immune characteristics and immunotherapy efficacies were explored. In addition, a platelet risk score (PRS) was generated for individual prognosis and verified the ability to predict prognosis, precise TME phenotypes, and immunotherapy efficacies.Results: Genes were clustered into two patterns that represented different TME phenotypes and had the ability to predict immunotherapy efficacy. We constructed a PRS that could predict individual prognosis with satisfactory accuracy using TCGA-BLCA. The results remained consistent when PRS was validated in the GSE32894 and Xiangya cohort. Moreover, we found that our PRS was positively related to tumor-infiltrating lymphocytes (TILs) in the TCGA-BLCA and Xiangya cohort. As expected, patients with higher PRS exhibited more sensitive to immunotherapy than patients with lower PRS. Finally, we discovered that a high PRS indicated a basal subtype of BLCA, whereas a low PRS indicated a luminal subtype.Conclusion: Platelet-related genes could predict TME phenotypes in BLCA. We constructed a PRS that could predict the TME, prognosis, immunotherapy efficacy, and molecular subtypes in BLCA. |
| first_indexed | 2024-04-09T14:26:08Z |
| format | Article |
| id | doaj.art-7a2723a5d5864a71a2e7219684032b56 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-09T14:26:08Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-7a2723a5d5864a71a2e7219684032b562023-05-04T04:35:06ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-05-011410.3389/fphar.2023.11877001187700A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohortsDingshan Deng0Dingshan Deng1Xiaowen Li2Tiezheng Qi3Yuanqing Dai4Yuanqing Dai5Neng Liu6Neng Liu7Huihuang Li8Huihuang Li9Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaXiangya School of Medicine, Central South University, Changsha, Hunan, ChinaXiangya School of Medicine, Central South University, Changsha, Hunan, ChinaDepartment of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaTeaching and Research Section of Clinical Nursing, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaBackground: Although the durable efficacy of immune checkpoint inhibitors (ICIs) in BLCA has been confirmed in numerous studies, not all patients benefit from their application in the clinic. Platelets are increasingly being found to be closely associated with cancer progression and metastasis; however, their comprehensive role in BLCA remains unclear.Methods: We comprehensively explored platelet expression patterns in BLCA patients using an integrated set of 244 related genes. Correlations between these platelet patterns with tumor microenvironment (TME) subtypes, immune characteristics and immunotherapy efficacies were explored. In addition, a platelet risk score (PRS) was generated for individual prognosis and verified the ability to predict prognosis, precise TME phenotypes, and immunotherapy efficacies.Results: Genes were clustered into two patterns that represented different TME phenotypes and had the ability to predict immunotherapy efficacy. We constructed a PRS that could predict individual prognosis with satisfactory accuracy using TCGA-BLCA. The results remained consistent when PRS was validated in the GSE32894 and Xiangya cohort. Moreover, we found that our PRS was positively related to tumor-infiltrating lymphocytes (TILs) in the TCGA-BLCA and Xiangya cohort. As expected, patients with higher PRS exhibited more sensitive to immunotherapy than patients with lower PRS. Finally, we discovered that a high PRS indicated a basal subtype of BLCA, whereas a low PRS indicated a luminal subtype.Conclusion: Platelet-related genes could predict TME phenotypes in BLCA. We constructed a PRS that could predict the TME, prognosis, immunotherapy efficacy, and molecular subtypes in BLCA.https://www.frontiersin.org/articles/10.3389/fphar.2023.1187700/fullplateletbladder carcinomaimmunotherapyprognosistumor microenvironment |
| spellingShingle | Dingshan Deng Dingshan Deng Xiaowen Li Tiezheng Qi Yuanqing Dai Yuanqing Dai Neng Liu Neng Liu Huihuang Li Huihuang Li A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts Frontiers in Pharmacology platelet bladder carcinoma immunotherapy prognosis tumor microenvironment |
| title | A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts |
| title_full | A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts |
| title_fullStr | A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts |
| title_full_unstemmed | A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts |
| title_short | A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts |
| title_sort | novel platelet risk score for stratifing the tumor immunophenotypes treatment responses and prognosis in bladder carcinoma results from real world cohorts |
| topic | platelet bladder carcinoma immunotherapy prognosis tumor microenvironment |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1187700/full |
| work_keys_str_mv | AT dingshandeng anovelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT dingshandeng anovelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT xiaowenli anovelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT tiezhengqi anovelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT yuanqingdai anovelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT yuanqingdai anovelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT nengliu anovelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT nengliu anovelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT huihuangli anovelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT huihuangli anovelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT dingshandeng novelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT dingshandeng novelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT xiaowenli novelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT tiezhengqi novelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT yuanqingdai novelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT yuanqingdai novelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT nengliu novelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT nengliu novelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT huihuangli novelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts AT huihuangli novelplateletriskscoreforstratifingthetumorimmunophenotypestreatmentresponsesandprognosisinbladdercarcinomaresultsfromrealworldcohorts |